HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples

Hruza, C; Dobianer, Karl; Beck, A.; Czerwenka, K.; Hanak, H; Klein, Michael; Leodolter, Sepp; Medl, M.; Müllauer-Ertl, Susanne; Preiser, Julius; Rosen, Alexander C.; Sälzer, H.; Sevelda, P.; Spona, J

doi:10.1016/0959-8049(93)90301-u

Cited by 28 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCR studies showed that the FGF3 gene was amplified in 20% of ovarian cancer samples and that this was significantly associated with FIGO stage but not with overall survival. [4][5][6] Normal ovarian surface epithelium does not express the Fibroblast Growth Factors (FGFs) have been implicated in malignant transformation, tumor mitogenesis, angiogenesis and chemoresistance. The aim of this study was to determine which FGFs and FGFRs play functional roles in epithelial ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

“…however, data on the inhibition of FGFR1 suggest that broad spectrum FGFR inhibitors may have unexpected effects on proliferation. Rhona McVey, 4 henry Kitchener 5 and Gordon c. Jayson mRNA for FGFR2 IIIb but does express FGF1 and FGF7. In contrast, FGFR2 IIIb is expressed in 80% of epithelial ovarian carcinomas, whereas FGF1 and FGF7 were only expressed in 20% and 60% of epithelial ovarian carcinomas, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Cole

Lau

Backen

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Cole

Lau

Backen

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…In breast cancer, the correlation between tumor progression and the c-erbB-2 gene am plification was also reported [24], Determina tion by PCR of the copy number of c-erbB-2 gene in breast cancer [25,26] and c-erbB-2 and INT-2 in ovarian cancer [27] has been documented. This PCR system, called differ ential PCR and using another set of primers as an internal control, can give a rough copy number.…”

Section: Discussionmentioning

confidence: 94%

Competitive Polymerase Chain Reaction for the Quantification of N-myc Gene Copy Number in Neuroblastoma

Inoue¹,

Hasan²,

Hemmi³

et al. 1996

Tumor Biol

View full text Add to dashboard Cite

An absolute quantification method for the N-myc gene copy number of neuroblastoma specimens was established by applying the competitive polymerase chain reaction (cPCR). The competitor plasmid (pZH2) lacking an Mlul site in the exon 2 was constructed to distinguish two product species amplified from genomic DNA and the competitor plasmid. By using this cPCR system, we could obtain qualitative results within 1 day, i.e. amplified or unamplified, and quantitative results by using radiolabelled nucleotides within 4 days. The copy numbers of N-myc in 47 neuroblastoma specimens by cPCR correlated well with those by Southern hybridization (r = 0.85). We conclude that cPCR is a simple and rapid method, requires only a small amount (200 ng) of sample DNA, and is expected to be used for prognostic evaluation in neuroblastomas.

show abstract

“…In addi tion, a single copy control from placental DNA and a negative control (PCR mix without DNA) were included in each PCR run. Electro phoresis of DNA products and densitométrie evaluation were per formed as described previously [4],…”

Section: Tissuementioning

confidence: 99%

“…The current clinical treatment is also similar to that for ovarian epithe lial tumors [3], But with an approximate response rate of 80%, but only a 20% 5-year survival [3], some progress in the understanding of the tumor biology is necessary to improve treatment. The HER-2 (neu/c-erbB-2) oncogene was reported to be amplified in 40.3% of human ovarian carcinomas [4], Although the situation is still controver sial, it is thought to be a valuable parameter with a worse prognosis for patients with amplified HER-2The aim of the present study was to investigate amplif ication of the HER-2 oncogene, estrogen receptor (ER), progesterone receptor (PgR) and clinicopathological in dices in fallopian tube carcinoma in order to shed more light on the biology of this tumor.Prof. Dr. J. Spona…”

mentioning

confidence: 99%

HER-2 Oncogene Is Not Amplified in Primary Carcinoma of the Fallopian Tube

Stühlinger

Rosen²,

Dobianer³

et al. 1995

Oncology

View full text Add to dashboard Cite

73 women suffering from primary carcinoma of the fallopian tube underwent surgical excision of their tubes. The tissue was embedded in paraffin and investigated for HER-2 oncogene amplification with a quantitative polymerase chain reaction method. DNA could be extracted and successfully prepared in 65/73 samples. None of the tissue samples exhibited amplified the HER-2 oncogene. Data suggest that the HER-2 oncogene does not play a role in tumor transformation and progression in fallopian tube carcinomas. This contrasts with observations in ovarian carcinomas, with which fallopian tube carcinomas share many clinical, histological and biochemical similarities.

show abstract

HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples

Cited by 28 publications

References 13 publications

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Competitive Polymerase Chain Reaction for the Quantification of N-<i>myc</i> Gene Copy Number in Neuroblastoma

<i>HER-</i><i>2</i> Oncogene Is Not Amplified in Primary Carcinoma of the Fallopian Tube

Contact Info

Product

Resources

About